CVS Health’s Sell-Side Score Turns Bullish, but a Key Analyst Metric Comes With Caveats

CVS Health (NYSE: CVS) is receiving a bullish tilt from Wall Street analysts, at least on one commonly cited rating yardstick. In a June 4, 2026 report syndicated by Yahoo Finance, Zacks Equity Research said CVS’s average brokerage recommendation, or ABR, came in at 1.32 on a 1-to-5 scale that ranges from Strong Buy to Strong Sell. On that scale, Zacks described 1.32 as approximating between Strong Buy and Buy.

According to the same note, the ABR calculation drew on recommendations from 25 brokerage firms. Zacks reported that 20 of those calls were “Strong Buy,” while two were “Buy.” The remaining recommendations did not fall into the Strong Buy or Buy categories described in the note.

Zacks framed ABR as a quick read on how brokerages are leaning, but also argued that it should not be treated as a standalone decision tool. The firm said brokerage recommendations often attract a “strong positive bias,” and it referenced its research that brokerage firms assign five Strong Buy ratings for every Strong Sell rating. Zacks also said research it cited suggests brokerage recommendations have little to no success in guiding investors toward stocks with the most potential for price appreciation.

The report emphasized that ABR is not the same measure as Zacks’s own ranking system. It said the ABR is calculated solely from broker calls and can be displayed in decimals (for example, 1.28). By contrast, Zacks described its Zacks Rank as a model built around earnings estimate revisions, shown as whole numbers from 1 to 5. Zacks added that ABR “is not necessarily up-to-date” when viewed by an investor, while Zacks Rank is designed to track changes in expected earnings more quickly.

For context, CVS Health’s business model spans pharmacy retail, pharmacy benefits management, and health insurance. In CVS’s investor materials, the company described its Pharmacy & Consumer Wellness segment as including retail pharmacies and related pharmacy services, and also referenced its footprint as of June 30, 2025, including about 9,000 retail pharmacy locations and a pharmacy benefits manager with approximately 87 million plan members. Those scale points help explain why analyst opinions on CVS can quickly spill across multiple parts of its integrated healthcare platform.

Beyond ABR, the June 4 note pointed to a separate announcement from earnings expectations. Zacks said the Zacks Consensus Estimate for CVS’s current year increased 4.1% over the prior month to $7.44, and it attributed the change to growing optimism among analysts over CVS’s earnings prospects. The firm said those dynamics contributed to a Zacks Rank of #2 (Buy) for CVS.

Still, the note left several practical questions unanswered for readers trying to connect the rating metric to specific fundamentals. It did not list the individual brokerage firms contributing to the 25-firm ABR survey, did not provide price targets, and did not attribute the optimism to particular CVS initiatives in areas such as pharmacy margins, insurance profitability, or care delivery. It also did not provide details on timing or magnitude of any operational changes beyond the movement in the consensus earnings estimate.

What to watch next is how quickly CVS’s earnings outlook and analyst revisions continue to move. If the consensus estimate keeps rising and the Zacks Rank remains in the buy category, that could reinforce positive sentiment that is already reflected in the ABR distribution. Separately, investors may want to monitor whether brokerages begin to change their recommendation mix after CVS’s next earnings update, since Zacks’s own caveat was that ABR may lag behind the most current expectations captured by earnings revisions.